Figure 3From: Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyTTP (A) and PFS (B) (population of patients receiving everolimus as second-line treatment, n = 211). PFS, progression-free survival; TTP, time to progression.Back to article page